Cite
Friedman CF, Hainsworth JD, Kurzrock R, et al. Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study. Cancer Discov. 2021;doi: 10.1158/2159-8290.CD-21-0450.
Friedman, C. F., Hainsworth, J. D., Kurzrock, R., Spigel, D. R., Burris, H. A., Sweeney, C. J., Meric-Bernstam, F., Wang, Y., Levy, J., Grindheim, J., Shames, D. S., Schulze, K., Patel, A., & Swanton, C. (2021). Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study. Cancer discovery, . https://doi.org/10.1158/2159-8290.CD-21-0450
Friedman, Claire F, et al. "Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study." Cancer discovery vol. (2021). doi: https://doi.org/10.1158/2159-8290.CD-21-0450
Friedman CF, Hainsworth JD, Kurzrock R, Spigel DR, Burris HA, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Grindheim J, Shames DS, Schulze K, Patel A, Swanton C. Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study. Cancer Discov. 2021 Dec 07; doi: 10.1158/2159-8290.CD-21-0450. Epub 2021 Dec 07. PMID: 34876409.
Copy
Download .nbib